晚期冠状瘤中CDK4/6抑制:NCT PMO-1601试验的最终结果
M-V Teleanu1, C E Heilig2, S Pirmann3
1Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Consortium (DKTK), Core Center Heidelberg, Heidelberg, Germany.
ESMO open
|July 8, 2025
概括
帕尔博西克利布在晚期心脏瘤中表现出适度的抗瘤活性,达到其主要终点. 未来的研究应该探索组合疗法,以提高这种罕见癌症的疗效.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 冠状瘤是一种极为罕见的骨癌,缺乏经批准的全身疗法.
- 之前的研究表明,palbociclib对抗CDKN2A缺乏的冠状瘤细胞系的潜力.
- 这项研究调查了palbociclib在晚期冠状瘤患者的疗效.
研究的目的:
- 为了评估palbociclib的抗瘤反应在患有晚期心脏瘤的患者.
- 确定疾病控制率 (DCR) 作为主要终点.
- 探索无进展生存率,整体生存率,并进行生物标志物分析.
主要方法:
- 进行了第二阶段,单臂,开放标签试验.
- 纳入了患有晚期冠状瘤和特定遗传标记 (CDKN2A损失,保留的CDK4/6和RB1) 的成年患者.
- 主要终点是在六个周期后通过RECISTv1.1进行DCR,研究成功率为25%.
主要成果:
- 评估了28名患者,随访时间中位数为28个月.
- DCR为39%,其中11名患者的病情稳定;没有观察到客观反应.
- 中位数无进展生存时间为5.6个月,中位数整体生存时间为24.6个月.
- 生物标志物分析显示了PIK3CA,PTEN,MTAP或MET基因的可操作变化.
结论:
- 该试验满足了其主要终点,显示了palbociclib在晚期瘤中适度的抗瘤活性.
- 帕尔博西克利布被很好地容忍,没有新的安全问题.
- 未来的战略应侧重于量身定制的分子组合疗法,以提高心脏瘤的治疗疗效.
相关概念视频
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
02:15M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K